// App-Quantinova.ai

: MERTK inhibition in the leukemia microenvironment promotes a therapeutic immune response to acute lymphoblastic leukemia

Researchers

Presenter

  • Kristen M Jacobsen

Principal Investigators

  • Alisa B. Lee-Sherick

  • Madeline G. Huey

  • Lauren S. Page

  • Weihe Zhang

  • Xiaodong Wang

  • Stephen V. Fyre

  • H. Shelton Earp

  • Craig T. Jordan

  • Deborah DeRyckere

  • Douglas K. Graham

Medical Centers

  • Dept. of Pediatrics, Emory Univ

  • Dept. of Pediatrics, Univ. of Colorado Anschutz Medical Campus

  • Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC

  • Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine

  • Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine

  • Division of Hematology, Univ. of Colorado Anschutz Medical Campus

  • Aflac Cancer & Blood Disorders Center, Children’s Healthcare of Atlanta

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 4

  • Programmed cell death 1 ligand 2

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Forkhead Box P3

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved